Malignant Bone Tumors

Modern Study Review (AI-Generated)

High-Yield Summary

Malignant bone tumors are a heterogeneous group of primary bone neoplasms with distinct clinical, radiographic, and histopathologic features. Early diagnosis and multidisciplinary management are critical to optimize pain control, preserve function, and improve survival. Current treatment paradigms emphasize neoadjuvant chemotherapy for high-grade sarcomas, precise surgical resection with limb salvage when feasible, and tailored adjuvant therapies based on tumor biology and staging.

Key Diagnostic Findings

Anatomy

• Most malignant bone tumors arise in the metaphysis or diaphysis of long bones, but some have predilections for axial skeleton (e.g., chordoma in sacrum/base of skull).
• Tumor location correlates with tumor type and age group.

Clinical Presentation

• Pain: Often progressive, deep, and worse at night or rest.
• Systemic symptoms: Fever, weight loss, and malaise (B symptoms) especially in Ewing sarcoma and multiple myeloma.
• Mass: Palpable soft tissue swelling or mass in advanced cases.
• Age distribution:
• Osteosarcoma: 10-20 years
• Ewing sarcoma: 5-30 years
• Chondrosarcoma: 30-70 years
• Others typically >30 years

Imaging

Classification Systems

• Osteosarcoma: Graded by histologic subtype (conventional, telangiectatic, parosteal, periosteal).
• Chondrosarcoma: Graded I (low), II (intermediate), III (high) based on cellularity and atypia.
• Ewing Sarcoma: Defined by molecular translocation t(11;22)(q24;q12).
• Others: Classified by histology and clinical behavior; no universal staging system but AJCC TNM staging applies.

Current Gold Standard Treatment

Non-operative Indications and Treatment

• Multiple myeloma: Primarily medical management with chemotherapy, radiotherapy, and supportive care.
• Low-grade chondrosarcoma: Selected cases may be observed or treated with curettage if surgery is high risk.
• Palliative care: For unresectable tumors or poor surgical candidates.

Operative Indications and Treatment

Modern Complications & Outcomes

Complications

• Local recurrence: Most common with inadequate margins or high-grade tumors.
• Metastasis: Pulmonary metastases are frequent in osteosarcoma and Ewing sarcoma.
• Chemotherapy toxicity: Myelosuppression, cardiotoxicity (doxorubicin), nephrotoxicity (cisplatin).
• Surgical complications: Infection, neurovascular injury, prosthetic failure in limb salvage.
• Pathologic fractures: Especially in multiple myeloma and advanced tumors.

Outcomes

• Osteosarcoma: 5-year survival ~60-70% with modern chemotherapy and surgery.
• Ewing Sarcoma: 5-year survival ~70% with multimodal therapy.
• Chondrosarcoma: Prognosis depends on grade; low-grade tumors have excellent outcomes with surgery alone.
• Multiple Myeloma: Median survival improved with novel agents but remains incurable; focus on quality of life.
• Limb salvage: Achievable in >80% of cases with modern imaging and surgical techniques, improving function and quality of life.

Classic Clinical Notes

Malignant Bone Tumors

Investigations: XR, MRI, Bone Scan, Bx, CXR & CT chest.

1) Osteosarcoma

• Location: Metaphysis of long bones
• Age: 10-20 years
• Symptoms: Rest pain
• Imaging: Radiolucent & dense (sunburst), cortical destruction, soft tissue mass
• Histology: Osteoid producing spindle cells
• Variations: Telangiectatic, parosteal, periosteal
• Treatment: Chemotherapy (pre & post op), wide resection

2) Chondrosarcoma

• Primary: Central metadiaphyseal, lucent with calcification (popcorn), scalloping
• Secondary: Proximal & axial, osteochondroma with large (>2cm) soft tissue mass
• Symptoms: Dull, aching pain
• Age: 30-70 years
• Grades: High (III), intermediate (II), low (I)
• Treatment: Wide or radical resection; adjuvant not effective

3) Ewing’s Sarcoma

• Origin: Non-mesenchymal elements of bone marrow
• Imaging: Permeative, destructive with soft tissue mass & periosteal reaction (onion skin)
• Age: 5-30 years
• Symptoms: B symptoms & pain
• Histology: Hypervascular, small round cells, positive periodic acid Schiff (PAS) for glycogen
• Genetics: Chromosome 11 & 22 translocation
• Treatment: Chemotherapy, local control (wide resection ± radiotherapy), chemotherapy

4) Fibrosarcoma

• Imaging: Destructive, lucent, metaphyseal lesion
• Location: Long bones
• Symptoms: Painful
• Age: >30 years
• Histology: Herringbone pattern of collagen
• Treatment: Wide or radical resection ± adjuvant

5) Chordoma

• Origin: Remnant of fetal notochord
• Location: Sacrococcygeal > base of skull > spine
• Imaging: Central vertebral body, anterior soft tissue mass, radiolucent
• Treatment: Wide resection, insensitive to adjuvant

6) Malignant Fibrous Histiocytoma (MFH)

• Origin: Arise from Paget’s disease or bone infarct
• Age: >30 years
• Metastasis: Lymphatic
• Imaging: Destructive, lucent
• Treatment: Radical resection or wide + adjuvant

7) Multiple Myeloma

• Pathology: Plasma cell malignancy
• Imaging: Lucency, cold bone scan
• Symptoms: B symptoms & renal failure
• Labs: Increased gamma A/B globulins on serum immunoelectrophoresis and Bence-Jones proteins in urine and serum
• Treatment: Radiotherapy; adjuvant chemotherapy; surgical stabilization

Last Updated on January 25, 2026 by orthonet